Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Food Effect of SYHA1402 in Healthy Subjects
NCT04453618Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of syha1402 in diabetic peripheral neuropathy (DPN) (4 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to infinity and 2 more. Status: unknown.
02
Drugs
syha1402
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT04453618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04453618.